Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00022399
• Other study ID #: J0007
• Secondary ID: P50CA058236P30CA
• Status: Completed
• Phase: Phase 2
• Start date: April 25, 2002
• Est. completion date: January 31, 2005

Study information

• Verified date: February 2019
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.

PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before surgery to remove the prostate in treating patients who have localized prostate cancer.

Description:

OBJECTIVES:

• Compare biomarker modulation (prostaglandin levels) in tissue samples of patients with localized prostate cancer treated with neoadjuvant celecoxib vs placebo followed by prostatectomy.

• Compare the effect of these regimens on angiogenic factors within the prostate in these patients.

• Determine the pharmacokinetic and pharmacodynamic effects of celecoxib in these patients.

• Compare the toxicity profiles of these regimens in these patients.

• Compare the compliance of patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral neoadjuvant celecoxib twice daily.

• Arm II: Patients receive oral neoadjuvant placebo twice daily. Treatment in both arms continues for at least 4 weeks followed by prostatectomy.

Patients are followed within 1 month and then at 3 months.

PROJECTED ACCRUAL: A total of 60-70 patients (at least 30 per arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: January 31, 2005
• Est. primary completion date: January 31, 2005
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following:

• Gleason sum at least 7

• Prostate-specific antigen (PSA) at least 15 ng/mL

• Clinical stage T2b or T2c (stage II)

• Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45%

• At least 3 positive core biopsies

• Planned radical prostatectomy

• No metastatic disease secondary to prostate cancer

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-1

Life expectancy:

• Not specified

Hematopoietic:

• WBC greater than 3,000/mm^3

• Platelet count greater than 100,000/mm^3

• Hemoglobin greater than 9 g/dL

• No history of bleeding disorders

Hepatic:

• Bilirubin less than 1.5 mg/dL

• AST/ALT less than 1.5 times upper limit of normal

• No viral hepatitis

Renal:

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance at least 50 mL/min

Other:

• No history of hypersensitivity and/or adverse reactions to salicylates

• No allergy to sulfa-containing medications

• No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer

• No medical or psychiatric problem that would preclude study participation

• No active infection

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior immunologic therapy for prostate cancer

Chemotherapy:

• At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

• No prior androgen ablation for prostate cancer

• At least 4 weeks since prior hormonal therapy and recovered

• At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids

• No concurrent glucocorticoids

Radiotherapy:

• At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered

Surgery:

• See Disease Characteristics

• At least 4 weeks since prior major surgery and recovered

Other:

• No prior investigational therapy for prostate cancer

• No prior or concurrent chronic anticoagulants

• No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib)

• At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA)

• At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs)

• At least 24 hours since prior use and no concurrent use of any of the following:

• Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole

• No aspirin (100 mg/day) within 1 week prior to surgery

• No concurrent addition of vitamins or herbal supplements

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• celecoxib
400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
• Placebos
Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib i — View Citation